Results 121 to 130 of about 43,637 (267)

Multitarget Regulatory Mechanisms and Research Advances of Plant‐Derived Bioactive Ingredients in Hypertension Prevention and Management

open access: yesPhytotherapy Research, EarlyView.
Schematic overview of the multi‐target and multi‐pathway mechanisms of PDBI in the prevention and management of hypertension. ABSTRACT Hypertension remains a major global risk factor for cardiovascular diseases, yet current treatments face challenges such as suboptimal blood pressure control and inadequate organ protection.
Qiqi Deng   +6 more
wiley   +1 more source

Self‐Organized Vascularized Human Liver Spheroids: Serum‐Free Culture Conditions and Use as Tissue Building Blocks

open access: yesSmall, EarlyView.
This approach addresses a major challenge in tissue engineering: creating larger, vascularized tissues. Microvascular networks in liver spheroids are developed through self‐organization mediated by mesenchymal stem cells. These spheroids are maintained in serum‐reduced or serum‐free medium and serve as building blocks to form planar tissue layers ...
Alina Filatova   +10 more
wiley   +1 more source

Artificial intelligence empowers targeted protein degradation: Core technological innovations, multi‐scenario applications, and translational prospects

open access: yesSmart Molecules, EarlyView.
AI is transforming TPD by improving the design, prediction, and optimization of degraders such as PROTACs, molecular glues, and LYTACs. This review summarizes key AI‐driven advances, highlights applications across drug discovery stages, and discusses remaining challenges and future directions for accelerating the development of therapies against ...
Shuanglin Qin   +10 more
wiley   +1 more source

Integrative Analysis of Plasma Proteome and Genome Reveals Novel Drug Targets for Chronic Rhinosinusitis and Nasal Polyps

open access: yesWorld Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Background Chronic rhinosinusitis (CRS) and nasal polyps (NP) are chronic inflammatory conditions with unsatisfactory treatment outcomes due to frequent recurrence of refractory disease. Identifying new therapeutic targets is essential. Methods We conducted a proteome‐wide Mendelian randomization (MR) analysis by integrating genome‐wide ...
En Zhou   +4 more
wiley   +1 more source

Role of CYP3A4 in kinase inhibitor metabolism and assessment of CYP3A4 activity

open access: yesTranslational Cancer Research, 2017
Gerd Mikus, Kathrin Isabelle Foerster
openaire   +1 more source

Advent of NK3R Antagonists for the Treatment of Menopausal Hot Flushes: A Narrative Review

open access: yesBJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT The menopause transition is marked by symptoms predominantly attributed to declining oestrogen levels. Approximately 80% of women experience associated symptoms, and 25% experience severe symptoms. The commonest are vasomotor symptoms (VMS), collectively referring to hot flushes and/or night sweats.
Aaran H. Patel   +5 more
wiley   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

open access: yesBritish Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu   +6 more
wiley   +1 more source

Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review

open access: yesBritish Journal of Pharmacology, EarlyView.
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß   +3 more
wiley   +1 more source

Bruton tyrosine kinase inhibitors and cardiovascular adverse events

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Bruton tyrosine kinase inhibitors (BTKi) have transformed the management of chronic lymphocytic leukaemia and other B‐cell malignancies, yet their therapeutic benefit is tempered by clinically relevant cardiovascular toxicities (predominantly atrial fibrillation, hypertension, bleeding and ventricular arrhythmias).
Massimiliano Camilli   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy